Primary rectal diffuse large B-cell lymphoma associated with ulcerative colitis: a case report

<table>
<thead>
<tr>
<th>勘者別名</th>
<th>寺島 秀夫</th>
<th>間宮 孝</th>
</tr>
</thead>
<tbody>
<tr>
<td>題名</td>
<td>Primary rectal diffuse large B-cell lymphoma associated with ulcerative colitis: a case report</td>
<td></td>
</tr>
<tr>
<td>報道誌</td>
<td>Clinical Case Reports</td>
<td></td>
</tr>
<tr>
<td>号</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>頁</td>
<td>150-155</td>
<td></td>
</tr>
<tr>
<td>発行年</td>
<td>2015-03</td>
<td></td>
</tr>
</tbody>
</table>

(C) 2014 The Authors.
Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

URL http://hdl.handle.net/2241/00135260
doi: 10.1002/ccr3.185
Primary rectal diffuse large B-cell lymphoma associated with ulcerative colitis: a case report

Kazuhiro Hiyama, Hideo Terashima, Yoritaka Nakano, Masahiro Kamiga, Kyoichi Harada, Hisashi Horiguchi, & Takashi Mamiya

1Department of Surgery, Hitachi Ltd. Hitachinaka General Hospital, Hitachinaka, Ibaraki, Japan
2Hitachinaka Medical Education and Research Center, University of Tsukuba Hospital, Hitachinaka, Ibaraki, Japan
3Department of Hematology, Hitachi Ltd. Hitachinaka General Hospital, Hitachinaka, Ibaraki, Japan
4Department of Pathology, Hitachi Ltd. Hitachinaka General Hospital, Hitachinaka, Ibaraki, Japan

Correspondence
Hideo Terashima, 20-1 Ishikawa-cho, Hitachinaka, Ibaraki, Japan.
Tel: +81-29-354-5111;
Fax: +81-29-354-6842;
E-mail: h-tera@md.tsukuba.ac.jp

Funding Information
No funding information provided.

Received: 19 August 2014; Revised: 19 October 2014; Accepted: 25 October 2014

Clinical Case Reports 2015; 3(3): 150–155
doi: 10.1002/ccr3.185

Key Clinical Message
We need to be aware of primary intestinal lymphoproliferative disease (PILD) associated with ulcerative colitis (UC). We should carefully monitor UC patients, particularly patients who meet the following conditions; a previous Epstein-Barr virus infection, treatment duration ≥4 years, male, and age ≥50 years.

Keywords
Azathioprine, Epstein-Barr virus, lymphoproliferative disease, ulcerative colitis.

Introduction
There are three main types of drugs that are commonly used to treat ulcerative colitis (UC): aminosalicylates, corticosteroids, and immunosuppressants [1, 2]. All drugs can have unwanted side effects, but some adverse effects gain little attention in spite of their severity. One such complication is primary intestinal lymphoproliferative disease (PILD), which can develop during the treatment of UC, especially in cases in which the patients are treated with immunosuppressants [1]. Although UC itself is not considered to be a risk factor for PILD, UC patients that are treated with thiopurines are considered to be at a significantly high risk of PILD [1, 3–5]. This case raises issues concerning what we should deal with the risk for UC treatment-associated PILD.

Case History/Examination
A 69-year-old male had suffered from progressively worsening pain and swelling in his right buttock for 1 month. The patient had been diagnosed with distal (left-sided) UC three and a half years ago (Fig. 1). Since then, his UC had become more extensive over time, resulting in total colitis requiring triple-drug combination therapy involving prednisolone (PSL), mesalazine (5-ASA), and azathioprine (AZA). At this visit, he had been taking 7.5 mg PSL, 2 g 5-ASA, and 50 mg AZA daily. The cumulative dose of PSL and AZA had reached 11,693.5 and 37,250 mg respectively. On inspection, the swelling and redness affecting his right buttock indicated the presence of strong inflammation.

Other than the abovementioned conditions, there was nothing in the patient’s medical, social, or family history that deserves special mention.

Blood tests revealed a total white blood cell count of 9100/μL and a mildly elevated C-reactive protein level of 10.24 mg/dL.

A contrast-enhanced computed tomography scan detected partial defects in the rectal wall and a mixture of gas bubbles and liquid that had spread from the tissues surrounding the rectum to the subcutaneous tissue, which were suggestive of necrotizing proctitis and the presence of a severe perirectal abscess (Fig. 2).
It comes down to whether UC had a causal role in the development of necrotizing proctitis with severe perirectal abscess; for example, fistula formation or perforated rectal cancer secondary to UC. Other causes included a variety of infectious proctitis with a more fulminant course, perforation of the rectal cancer unrelated to UC, and so on.

Immediately, the patient underwent emergency surgery including removal of abscess with necrotic tissue, drainage, and ileostomy. In addition to systemic administration of doripeneme hydrate, the wound left open was managed by wound cleansing with the use of normal saline squeeze bottles two times daily.

Outcome and Follow-Up

Daily wound cleansing and the systemic administration of antibiotics based on antimicrobial susceptibility testing was continued for about 1 month, but the pelvic infection remained poorly controlled. We considered that the underlying cause of the infection was the long-term administration of corticosteroids and immunosuppressants and that the residual necrotic tissue had become a breeding ground for bacteria. On day 42 after the emergent surgery, the patient underwent laparoscopy-assisted total colorectectomy and the removal of the necrotic tissue followed by omentopexy with the aim of controlling the infection and promoting wound healing in the pelvic cavity.

A routine histopathological examination of the surgical specimen (Fig. 3A) confirmed that the UC extended to the entire colon (Fig. 3B), and surprisingly revealed the existence of malignant lymphoma in the rectal ulcer. A further detailed examination identified Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV-positive DLBCL) in the rectum (Fig. 3C). Imaging studies and a bone marrow biopsy were performed, which did not find any evidence of pathological lymphadenopathy or bone marrow infiltration. Therefore, we clinically diagnosed the
Figure 3. (A) Total colectomy specimen. The white arrow indicates the site from where the colonic tissue slices that were subjected to the histopathological examination shown in (B) were obtained. The dotted white arrow indicates the site from where the rectal tissue slices that were subjected to the histopathological examination shown in (C) were obtained. (B) The sigmoid colon mucosa apart from the ulcer shows marked cryptic distortion with Paneth cell metaplasia, thickening of lamina muscularis mucosae, and relatively mild lymphocytic infiltration (compared to Fig. 1B); findings are consistent with ulcerative colitis in chronic phase. (C) Histologic section of the rectal ulcer demonstrates that there is dense cellular aggregation in the ulcer edge. High-power view shows that large tumor cells possess irregular-shaped nuclei and scant cytoplasm. Some nuclei are very large and contain prominent nucleoli, mimicking Hodgkin cells. Immunohistochemically, the tumor cells express CD20, and in situ hybridization analysis reveals their expression of Epstein-Barr virus encoded RNAs (EBERs).
patient with EBV-positive DLBCL arising from the rectum and considered that this condition represented a form of UC associated PILD.

As the infected wound failed to improve despite the withdrawal of PSL and AZA, a second attempt to remove the abscess and necrotic tissue followed by drainage was conducted on day 81 after admission. A histopathological examination of the granulation tissue surrounding the necrotic tissue demonstrated proliferating and infiltrating EBV-positive DLBCL cells (Fig. 4), indicating that the malignant lymphoma had relapsed locally and that it might have played a role in prolonging the patient’s infection.

As the DLBCL had to be treated in order to treat the infected wound, we started chemotherapy with the R-THP-CVP regimen (rituximab, therarubicin, cyclophosphamide, vindesine, and prednisolone) on day 96 after admission [6, 7]. However, the first course of chemotherapy had no effect. The patient became increasingly ill; in particular, urinary incontinence and lower limb dysesthesia developed and eventually a mixture of urine and digestive juices drained through the original wound, which was suggestive of extended tissue destruction due to the progression of both the malignant lymphoma and wound infection. The patient died of disseminated intravascular coagulation syndrome secondary to sepsis on day 144 after admission.

Discussion

We experienced a case of primary rectal DLBCL associated with UC, which had a unique clinical course that was unlike that of common malignant lymphoma. Generally, primary gastrointestinal lymphoma decreases the mechanical strength of the gastrointestinal wall by replacing intestinal tissues as it proliferates, which is considered to be causally related to perforation [8–10]. In the present case, the use of steroids (PSL) masked the inflammatory response that would have been induced when the patient suffered a rectal perforation, which led to a delay in the patient seeking medical care and the development of necrotizing proctitis by the time of his visit. Therefore, there was no choice but to treat the infected wounds as a large open wound, which made wound management difficult throughout the patient’s clinical course. A histopathological examination of the specimen obtained during the second debridement of the open wound showed that lymphoma cells had spread to the region around the granulation tissue and had also infiltrated and occluded some blood vessels. Thus, the locally recurrent lymphoma not only had a substantially detrimental effect on wound healing, but also caused further tissue destruction in the bladder and small intestine, resulting in the leakage of urine and stool from the open wound.

In this case, three factors, persistent chronic inflammation due to UC, a previous EBV infection, and the administration of AZA might have all contributed to the pathogenesis of the patient’s PILD; that is, primary rectal DLBCL. Persistent chronic inflammation might play a role in the promotion of the precursor cells of malignant lymphoma because it leads to an overstimulated immune system and the continuous proliferation of immune cells [11]. In addition, in the presence of over-activated immune T cell dysfunction would allow the reactivation of EBV, which mostly infects B cells [11]. The newly infected and differentiating B cells would not be controlled by cytotoxic T cell responses because of the T cell dysfunction, which could lead to uncontrolled lymphoproliferation and the subsequent development of malignant lymphoma [12, 13]. However, the incidence of PILD among UC patients is relatively low; that is, less than one in 1500 patients per year, indicating that UC itself is not a signifi-

Figure 4. (A) Lymphoma cells diffusely infiltrate the granulation tissue obtained during the second debridement. (B) Elastica van Gieson staining reveals their angiocentric feature.
cant risk factor for PILD [14–16]. In previous reports on
the causal relationship between inflammatory bowel dis-
ease and PILD, the relative risk of PILD associated with
irritable bowel disease (IBD) ranged from 0.4 to 17.51,
suggesting that several reports found no link between the
conditions [3, 4, 16]. On the other hand, UC patients
receiving thiopurines were found to exhibit markedly
increased relative risks of PILD, ranging between 2.97 and
49.52. This indicates that the use of thiopurines in UC
causes an increased risk of PILD [3, 5]. In addition, it has
been reported that in cases of PILD occurring in UC
patients receiving thiopurines more than 90% of them are
EBV-positive on histopathological examination [5, 15].
Form the standpoint of lymphomas, there have been
growing evidence indicating a significant causal relation-
ship between use of thiopurines and development of lymph-
oma [17, 18]. Especially, Khan et al. presented definite
results based on a retrospective, nationwide cohort study
including 4734 UC patients treated with thiopurines for a
median of 1 year [17]. The age-, gender-, and race-
adjusted hazard ratios of developing lymphoma were 4.2
(95% confidence interval, 2.5–6.8; \( P < 0.0001 \)) while being treated with thiopurines, and 0.5 (95% confidence
interval, 0.2–1.3; \( P = 0.17 \)) after discontinuing treatment
with thiopurines compared with unexposed patients. So,
it is extremely important that discontinuing thiopurine
therapy allows for reduction in the risk of lymphoma.

This case report highlights the side effects of drug ther-
apy for UC. Once the cumulative dose of PSL exceeds
10,000 mg, serious side effects, which might be irrevers-
able, are likely to develop [19]. Therefore, clinicians
should consider surgery before the cumulative dose of
oral corticosteroids reaches this threshold. In the case of
thiopurines, previous studies have produced conflicting
results whether the cumulative dose and/or duration of AZA are associated with the development of
PILD [3, 20, 21]. However, it should be noted that the
magnitude of overall risk for lymphomas is significantly
associated with therapy duration of 4 years as a threshold
for achieving statistical significance [17, 18]. At this time,
we should not overreact to the risk of PILD development
and stop using thiopurines because they benefit a lot of
UC patients [2], and the incidence of PILD among UC
patients receiving thiopurines is quite low (less than one
in 1000 patients per year) [1]. Since over 90% of adults
have been infected with EBV [22], it is not feasible to
decide whether the use of thiopurines is safe after testing
for the presence or absence of EBV. Instead, the most
practical approach is to monitor UC patients who are
taking thiopurines whilst paying careful attention to the
risk of PILD. In terms of overall risk for lymphomas, the
characteristics of patients requiring special care are as fol-
lows; treatment duration for more than 4 years, male
gender, and age older than 50 or 65 years [17, 18]. On
the other hand, a trial of withdrawal of thiopurine ther-
apy after 3 years may be another option, considering the
results reported by Khan et al. [17].

The outcome of and optimal treatment for UC-associated
PILD are disputed [15, 20, 21, 23, 24] because insufficient information is available about the condition due to
the limited number of case reports [20]. Therefore, fur-
ther collection and follow-up of reported cases are needed
to clarify the characteristics of PILD secondary to UC.

Conflict of Interest

None declared.

References

3. Beaugerie, L., N. Brousse, A. M. Bouvier, J. F. Colombel,
disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational
lymphoproliferative disorders in patients with inflammatory
5. Vos, A. C. W., N. Bakkal, R. C. Minnee, M. K. Casparie,
lymphoma in patients with inflammatory bowel diseases: a
Dutch nationwide study. Inflamm. Bowel Dis. 17:1837–
1843.
derivative of doxorubicin. THP-COP therapy for non-
7. Mitsuhashi, S., H. Ninomiya, A. Shibuya, H. Kojima, T.
regimen for elderly patients with malignant lymphoma.
Rinsho Ketsueki 34:1532–1539.
8. Vaidya, R., T. M. Habermann, J. H. Donohue, K. M.
perforation in intestinal lymphoma: incidence and clinical
10. Richards, M. A. 1986. Lymphoma of the colon and

© 2014 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.